The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 349:1971-1972 November 13, 2003 Number 20
NextNext

Paricalcitol, Calcitriol, and Survival of Patients Undergoing Hemodialysis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Teng, M.
-PubMed Citation
To the Editor: The rate of death from any cause among patients undergoing dialysis in the United States remained steady at 17 to 18 percent per year between 1996 and 2000.1 Thus, the finding by Teng et al. (July 31 issue)2 that patients undergoing dialysis who are treated with paricalcitol have a lower mortality rate than patients who are treated with calcitriol (18.0 percent vs. 22.3 percent per year) is more consistent with a harmful effect of calcitriol than a beneficial effect of paricalcitol. Teng et al. might have included in their analysis as true controls patients who were not . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.